The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| MEDP | +25.82% | +166.54% | +21.66% | +1,491% |
| S&P | +14.43% | +77.25% | +12.13% | +218% |
Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.
The biopharmaceutical processor posted another strong earnings result for the third quarter.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $708.45M | 32.0% |
| Gross Profit | $198.19M | 16.0% |
| Gross Margin | 27.97% | -3.9% |
| Market Cap | $15.82B | 53.2% |
| Market Cap / Employee | $2.55M | 0.0% |
| Employees | 6.2K | 5.1% |
| Net Income | $135.13M | 15.5% |
| EBITDA | $160.40M | 20.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $497.05M | -25.8% |
| Accounts Receivable | $402.08M | 35.6% |
| Inventory | 0 | 0.0% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $113.64M | -10.0% |
| Short Term Debt | $23.21M | -0.3% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 22.13% | 0.6% |
| Return On Invested Capital | 32.39% | 5.9% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $188.12M | 2.8% |
| Operating Free Cash Flow | $192.65M | 1.0% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 23.25 | 23.34 | 35.96 | 36.73 | 39.67% |
| Price to Book | 11.28 | 15.74 | 83.59 | 53.74 | 359.79% |
| Price to Sales | 4.41 | 4.10 | 6.28 | 6.43 | 28.05% |
| Price to Tangible Book Value | 72.30 | -90.78 | -27.50 | -39.22 | -170.16% |
| Price to Free Cash Flow TTM | 17.57 | 15.78 | 21.89 | 23.86 | 28.93% |
| Enterprise Value to EBITDA | 76.49 | 69.37 | 98.59 | 99.17 | 30.88% |
| Free Cash Flow Yield | 5.7% | 6.3% | 4.6% | 4.2% | -22.44% |
| Return on Equity | 65.8% | 89.4% | 73.7% | 70.2% | 20.25% |
| Total Debt | $150.35M | $149.83M | $143.97M | $136.85M | -8.47% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
